Skip to main content
Top
Published in: Allergy, Asthma & Clinical Immunology 1/2022

Open Access 01-12-2022 | Allergic Rhinitis | Research

Intranasal budesonide for rhinitis during a high airborne pollution period: a randomized controlled trial

Authors: Yuan Zhang, Chunguang Shan, Weiwei Liu, Yaozhong Han, Guanggang Shi, Yongjian Ma, Kerstin Wagner, Xiaoyan Tian, Lili Zhang, Allan Joseph Larona, Steven Sacavage, Kathleen Franklin, Chengshuo Wang, Luo Zhang

Published in: Allergy, Asthma & Clinical Immunology | Issue 1/2022

Login to get access

Abstract

Background

Air pollution may induce or reinforce nasal inflammation regardless of allergy status. There is limited direct clinical evidence informing the treatment of airborne pollution-related rhinitis.

Objective

To assess the effectiveness of intranasal budesonide in adults with self-reported rhinitis symptoms triggered/worsened by airborne pollution.

Methods

Adults in northern China with self-reported rhinitis symptoms triggered or worsened by airborne pollution were randomized to budesonide 256 µg/day or placebo for 10 days in pollution season (October 2019 to February 2020). The primary endpoint was the mean change from baseline in 24-h reflective total nasal symptom score (rTNSS) averaged over 10 days. The secondary endpoints were subject-assessed Global Impression of Change (SGIC), mean change from baseline in individual nasal symptom severity, and mean change from baseline in individual non-nasal symptoms of cough and postnasal drip severity. One-sided P < 0.0125 was considered statistically significant.

Results

After an interruption by COVID-19, an interim analysis showed that the study could be ended for efficacy with n = 206 participants (103/group) since the primary efficacy endpoint demonstrated significant results. The final efficacy results showed that the 10-day-averaged rTNSS change in the budesonide group was greater than with placebo (− 2.20 vs − 1.72, P = 0.0107). Budesonide also significantly improved 10-day-averaged itching/sneezing change (− 0.75 vs − 0.51, P = 0.0009). Results for SGIC and all other individual symptoms did not show significant differences between the two groups.

Conclusions

Intranasal budesonide 256 µg once daily improved the total nasal symptoms and itching/sneezing over 10 days in adults with rhinitis triggered/worsened by airborne pollution.
Appendix
Available only for authorised users
Literature
2.
go back to reference Fairweather V, Hertig E, Traidl-Hoffmann C. A brief introduction to climate change and health. Allergy. 2020;75(9):2352–4.CrossRef Fairweather V, Hertig E, Traidl-Hoffmann C. A brief introduction to climate change and health. Allergy. 2020;75(9):2352–4.CrossRef
3.
go back to reference D’Amato G, Pawankar R, Vitale C, Lanza M, Molino A, Stanziola A, et al. Climate change and air pollution: effects on respiratory allergy. Allergy Asthma Immunol Res. 2016;8(5):391–5.CrossRef D’Amato G, Pawankar R, Vitale C, Lanza M, Molino A, Stanziola A, et al. Climate change and air pollution: effects on respiratory allergy. Allergy Asthma Immunol Res. 2016;8(5):391–5.CrossRef
4.
go back to reference D’Amato G, Chong-Neto HJ, Monge Ortega OP, Vitale C, Ansotegui I, Rosario N, et al. The effects of climate change on respiratory allergy and asthma induced by pollen and mold allergens. Allergy. 2020;75(9):2219–28.CrossRef D’Amato G, Chong-Neto HJ, Monge Ortega OP, Vitale C, Ansotegui I, Rosario N, et al. The effects of climate change on respiratory allergy and asthma induced by pollen and mold allergens. Allergy. 2020;75(9):2219–28.CrossRef
5.
go back to reference Galan C, Thibaudon M. Climate change, airborne pollen, and pollution. Allergy. 2020;75(9):2354–6.CrossRef Galan C, Thibaudon M. Climate change, airborne pollen, and pollution. Allergy. 2020;75(9):2354–6.CrossRef
6.
go back to reference Shusterman D. Nonallergic rhinitis: environmental determinants. Immunol Allergy Clin North Am. 2016;36(2):379–99.CrossRef Shusterman D. Nonallergic rhinitis: environmental determinants. Immunol Allergy Clin North Am. 2016;36(2):379–99.CrossRef
7.
go back to reference Shusterman D. The effects of air pollutants and irritants on the upper airway. Proc Am Thorac Soc. 2011;8(1):101–5.CrossRef Shusterman D. The effects of air pollutants and irritants on the upper airway. Proc Am Thorac Soc. 2011;8(1):101–5.CrossRef
8.
go back to reference Mady LJ, Schwarzbach HL, Moore JA, et al. The association of air pollutants and allergic and non-allergic rhinitis in chronic rhinosinusitis. Int Forum Allergy Rhinol. 2018;8:369–76.CrossRef Mady LJ, Schwarzbach HL, Moore JA, et al. The association of air pollutants and allergic and non-allergic rhinitis in chronic rhinosinusitis. Int Forum Allergy Rhinol. 2018;8:369–76.CrossRef
9.
go back to reference Burte E, Leynaert B, Marcon A, et al. Long-term air pollution exposure is associated with increased severity of rhinitis in 2 European cohorts. J Allergy Clin Immunol. 2020;145(3):834-842.e6.CrossRef Burte E, Leynaert B, Marcon A, et al. Long-term air pollution exposure is associated with increased severity of rhinitis in 2 European cohorts. J Allergy Clin Immunol. 2020;145(3):834-842.e6.CrossRef
10.
go back to reference Greiner AN, Hellings PW, Rotiroti G, Scadding GK. Allergic rhinitis. Lancet. 2011;378(9809):2112–22.CrossRef Greiner AN, Hellings PW, Rotiroti G, Scadding GK. Allergic rhinitis. Lancet. 2011;378(9809):2112–22.CrossRef
11.
go back to reference Pipkorn U, Proud D, Lichtenstein LM, et al. Inhibition of mediator release in allergic rhinitis by pretreatment with topical glucocorticosteroids. N Engl J Med. 1987;316(24):1506–10.CrossRef Pipkorn U, Proud D, Lichtenstein LM, et al. Inhibition of mediator release in allergic rhinitis by pretreatment with topical glucocorticosteroids. N Engl J Med. 1987;316(24):1506–10.CrossRef
12.
go back to reference van Cauwenberge P, Bachert C, Passalacqua G, et al. Consensus statement on the treatment of allergic rhinitis. Allergy. 2000;55:116–34.CrossRef van Cauwenberge P, Bachert C, Passalacqua G, et al. Consensus statement on the treatment of allergic rhinitis. Allergy. 2000;55:116–34.CrossRef
13.
go back to reference Wallace DV, Dykewicz MS, Bernstein DI, et al. The diagnosis and management of rhinitis: an updated practice parameter. J Allergy Clin Immunol. 2008;122(2 Suppl):S1–84.CrossRef Wallace DV, Dykewicz MS, Bernstein DI, et al. The diagnosis and management of rhinitis: an updated practice parameter. J Allergy Clin Immunol. 2008;122(2 Suppl):S1–84.CrossRef
14.
go back to reference Downie SR, Andersson M, Rimmer J, Leuppi JD, Xuan W, Akerlund A, Peat JK, Salome CM. Symptoms of persistent allergic rhinitis during a full calendar year in house dust mite-sensitive subjects. Allergy. 2004;59(4):406–14.CrossRef Downie SR, Andersson M, Rimmer J, Leuppi JD, Xuan W, Akerlund A, Peat JK, Salome CM. Symptoms of persistent allergic rhinitis during a full calendar year in house dust mite-sensitive subjects. Allergy. 2004;59(4):406–14.CrossRef
15.
go back to reference Juniper EF, Guyatt GH. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy. 1991;21(1):77–83.CrossRef Juniper EF, Guyatt GH. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy. 1991;21(1):77–83.CrossRef
16.
go back to reference Meltzer EO. Clinical and antiinflammatory effects of intranasal budesonide aqueous pump spray in the treatment of perennial allergic rhinitis. Ann Allergy Asthma Immunol. 1998;81(2):128–34.CrossRef Meltzer EO. Clinical and antiinflammatory effects of intranasal budesonide aqueous pump spray in the treatment of perennial allergic rhinitis. Ann Allergy Asthma Immunol. 1998;81(2):128–34.CrossRef
17.
go back to reference Tantilipikorn P, Thanaviratananich S, Chusakul S, et al. Efficacy and safety of once daily fluticasone furoate nasal spray for treatment of irritant (Non-allergic) rhinitis. Open Respir Med J. 2010;4:92–9.CrossRef Tantilipikorn P, Thanaviratananich S, Chusakul S, et al. Efficacy and safety of once daily fluticasone furoate nasal spray for treatment of irritant (Non-allergic) rhinitis. Open Respir Med J. 2010;4:92–9.CrossRef
18.
go back to reference Nathan RA, Berger W, Yang W, et al. Effect of once-daily fluticasone furoate nasal spray on nasal symptoms in adults and adolescents with perennial allergic rhinitis. Ann Allergy Asthma Immunol. 2008;100(5):497–505.CrossRef Nathan RA, Berger W, Yang W, et al. Effect of once-daily fluticasone furoate nasal spray on nasal symptoms in adults and adolescents with perennial allergic rhinitis. Ann Allergy Asthma Immunol. 2008;100(5):497–505.CrossRef
19.
go back to reference Reinmuth-Selzle K, Kampf CJ, Lucas K, et al. Air Pollution and climate change effects on allergies in the anthropocene: abundance, interaction, and modification of allergens and adjuvants. Environ Sci Technol. 2017;51(8):4119–41.CrossRef Reinmuth-Selzle K, Kampf CJ, Lucas K, et al. Air Pollution and climate change effects on allergies in the anthropocene: abundance, interaction, and modification of allergens and adjuvants. Environ Sci Technol. 2017;51(8):4119–41.CrossRef
20.
go back to reference Deng SZ, Jalaludin BB, Antó JM, Hess JJ, Huang CR. Climate change, air pollution, and allergic respiratory diseases: a call to action for health professionals. Chin Med J. 2020;133(13):1552–60.CrossRef Deng SZ, Jalaludin BB, Antó JM, Hess JJ, Huang CR. Climate change, air pollution, and allergic respiratory diseases: a call to action for health professionals. Chin Med J. 2020;133(13):1552–60.CrossRef
21.
go back to reference Gerth van Wijk RG. de Graaf-in ’t Veld C, Garrelds IM. Nasal hyperreactivity. Rhinology. 1999;37(2):50–5.PubMed Gerth van Wijk RG. de Graaf-in ’t Veld C, Garrelds IM. Nasal hyperreactivity. Rhinology. 1999;37(2):50–5.PubMed
22.
go back to reference Segboer CL, Holland CT, Reinartz SM, Terreehorst I, Gevorgyan A, Hellings PW, et al. Nasal hyper-reactivity is a common feature in both allergic and non-allergic rhinitis. Allergy. 2013;68(11):1427–34.CrossRef Segboer CL, Holland CT, Reinartz SM, Terreehorst I, Gevorgyan A, Hellings PW, et al. Nasal hyper-reactivity is a common feature in both allergic and non-allergic rhinitis. Allergy. 2013;68(11):1427–34.CrossRef
23.
go back to reference Xian M, Ma S, Wang K, Lou H, Wang Y, Zhang L, et al. Particulate matter 25 causes deficiency in barrier integrity in human nasal epithelial cells. Allergy Asthma Immunol Res. 2020;12(1):56–71.CrossRef Xian M, Ma S, Wang K, Lou H, Wang Y, Zhang L, et al. Particulate matter 25 causes deficiency in barrier integrity in human nasal epithelial cells. Allergy Asthma Immunol Res. 2020;12(1):56–71.CrossRef
24.
go back to reference Ramanathan M Jr, London NR Jr, Tharakan A, Surya N, Sussan TE, Rao X, et al. Airborne particulate matter induces nonallergic eosinophilic sinonasal inflammation in mice. Am J Respir Cell Mol Biol. 2017;57(1):59–65.CrossRef Ramanathan M Jr, London NR Jr, Tharakan A, Surya N, Sussan TE, Rao X, et al. Airborne particulate matter induces nonallergic eosinophilic sinonasal inflammation in mice. Am J Respir Cell Mol Biol. 2017;57(1):59–65.CrossRef
25.
go back to reference Xian M, Wang K, Lou H, Wang Y, Zhang L, Wang C. Short-term haze exposure predisposes healthy volunteers to nasal inflammation. Allergy Asthma Immunol Res. 2019;11(5):632–43.CrossRef Xian M, Wang K, Lou H, Wang Y, Zhang L, Wang C. Short-term haze exposure predisposes healthy volunteers to nasal inflammation. Allergy Asthma Immunol Res. 2019;11(5):632–43.CrossRef
26.
go back to reference Bousquet J, Schünemann HJ, Togias A, et al. Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. J Allergy Clin Immunol. 2020;145(1):70-80.e3.CrossRef Bousquet J, Schünemann HJ, Togias A, et al. Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. J Allergy Clin Immunol. 2020;145(1):70-80.e3.CrossRef
27.
go back to reference Dykewicz MS, Wallace DV, Amrol DJ, et al. Rhinitis 2020: a practice parameter update. J Allergy Clin Immunol. 2020;146(4):721–67.CrossRef Dykewicz MS, Wallace DV, Amrol DJ, et al. Rhinitis 2020: a practice parameter update. J Allergy Clin Immunol. 2020;146(4):721–67.CrossRef
28.
go back to reference Uller L, Emanuelsson CA, Andersson M, Erjefalt JS, Greiff L, Persson CG. Early phase resolution of mucosal eosinophilic inflammation in allergic rhinitis. Respir Res. 2010;11:54.CrossRef Uller L, Emanuelsson CA, Andersson M, Erjefalt JS, Greiff L, Persson CG. Early phase resolution of mucosal eosinophilic inflammation in allergic rhinitis. Respir Res. 2010;11:54.CrossRef
Metadata
Title
Intranasal budesonide for rhinitis during a high airborne pollution period: a randomized controlled trial
Authors
Yuan Zhang
Chunguang Shan
Weiwei Liu
Yaozhong Han
Guanggang Shi
Yongjian Ma
Kerstin Wagner
Xiaoyan Tian
Lili Zhang
Allan Joseph Larona
Steven Sacavage
Kathleen Franklin
Chengshuo Wang
Luo Zhang
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Allergy, Asthma & Clinical Immunology / Issue 1/2022
Electronic ISSN: 1710-1492
DOI
https://doi.org/10.1186/s13223-022-00686-y

Other articles of this Issue 1/2022

Allergy, Asthma & Clinical Immunology 1/2022 Go to the issue